Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00405743

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

Sponsor: Clavis Pharma

Interventions CP-4055

Updated 7 times since 2017 Last updated: Sep 12, 2013 Started: May 31, 2006 Primary completion: May 31, 2009 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00405743, this PHASE1/PHASE2 trial focuses on AML and Hematologic Malignancies and remains completed. Sponsored by Clavis Pharma, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clavis Pharma

Data source: Clavis Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Bobigny, France , Bologna, Italy , Cleveland, United States , Durham, United States , Frankfurt am Main, Germany , Houston, United States , Lyon, France , Manchester, United Kingdom , Marseille, France and 6 more locations